IP Library Granted Patent US 9,522,243
Granted Patent B2
US 9,522,243 · App. 14/816,247 · Granted Dec 20, 2016

Nasal devices

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,522,243
App. No.
14/816,247
Granted
Dec 20, 2016
Kind
B2
Abstract

A nasal delivery device and a method of delivering substance to a nasal airway of a subject can be used for mass treatment, especially mass vaccination. The delivery device can include an interface unit, as a replaceable unit, having at least one nosepiece unit for fitting to a respective nostril of a subject, a nozzle from which substance is in use delivered, and at least one delivery unit having a substance supply unit for delivering substance to the nozzle of the at least one nosepiece unit. The delivery device can also include an actuation unit for actuating the at least one delivery unit of the interface unit.

Claims (21)

1. A nasal delivery device for delivering a substance to a nasal airway of a subject, comprising:

an interface unit configured to be attachable to an actuation unit, wherein the interface unit is attachable to the actuation unit in a first unaligned position and is movable to a second aligned position, wherein the interface unit is actuatable only in the aligned position;

the interface unit including a nosepiece unit, a mouthpiece and a delivery unit, the nosepiece unit configured for fitting to a respective nostril of the subject and the delivery unit including a substance supply unit actuatable to deliver the substance to the nosepiece unit.

2. The delivery device of claim 1 , wherein the substance is a powder.

3. The delivery device of claim 1 , wherein the substance is a liquid.

4. The delivery device of claim 1 , wherein the interface unit is a single integral unit.

5. The delivery device of claim 1 , wherein the delivery unit is actuated in response to exhalation by the subject.

6. The delivery device of claim 5 , wherein the mouthpiece and the nosepiece unit of the interface unit are fluidly connected.

7. The delivery device of claim 1 , wherein the interface unit is one of a plurality of interface units each attached to a common support.

8. The delivery device of claim 7 , wherein the common support is a belt.

9. A nasal delivery device for delivering a substance to a nasal airway of a subject, comprising:

an interface unit configured to be attachable to an actuation unit, wherein the interface unit is attachable to the actuation unit in a first unaligned position and is slidably movable through the unaligned position to a second aligned position, wherein the interface unit is actuatable only in the aligned position;

the interface unit including a nosepiece unit and a delivery unit, the nosepiece unit configured for fitting to a respective nostril of the subject and the delivery unit including a substance supply unit actuatable to deliver the substance to the nosepiece unit.

10. The delivery device of claim 9 , wherein the substance is a powder.

11. The delivery device of claim 9 , wherein the substance is a liquid.

12. The delivery device of claim 9 , wherein the interface unit is a single integral unit.

13. The delivery device of claim 9 , wherein the delivery unit is actuated in response to exhalation by the subject.

14. The delivery device of claim 9 , wherein the interface unit further comprises a mouthpiece.

15. The delivery device of claim 14 , wherein the mouthpiece and the nosepiece unit of the interface unit are fluidly connected.

16. The delivery device of claim 9 , wherein the interface unit is one of a plurality of interface units each attached to a common support.

17. The delivery device of claim 16 , wherein the common support is a belt.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded May 21, 2025
From: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
To: OPTINOSE INC.
Reel/Frame 071547/0979 →
CHANGE OF ADDRESS Recorded Jan 7, 2025
From: OPTINOSE, INC.
To: OPTINOSE, INC.
Reel/Frame 069833/0273 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2022
From: OPTINOSE AS
To: OPTINOSE INC
Reel/Frame 061546/0424 →
RELEASE OF SECURITY AGREEMENT RECORDED AT REEL 044976 FRAME 0505 Recorded Sep 13, 2019
From: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
To: OPTINOSE AS
Reel/Frame 050371/0894 →
SECURITY INTEREST Recorded Sep 13, 2019
From: OPTINOSE AS
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 050371/0913 →
SECURITY INTEREST Recorded Dec 29, 2017
From: OPTINOSE AS
To: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
Reel/Frame 044976/0505 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2017
From: DJUPESLAND, PER GISLE
To: OPTINOSE AS
Reel/Frame 042709/0486 →